Also published as: Sung-Hou Kim, H S Kim, Suhyung Kim, Jong-Ho Kim, Mi Ok Kim, Jong Heon Kim, S Y Kim, Chul-Hong Kim, Do Hyung Kim, Sydney Y Kim, Sung Young Kim, So Young Kim, Yeonsoo Kim, Chongtae Kim, Jiha Kim, Myung-Sunny Kim, Hyeong-Rok Kim, Young-Youn Kim, Hye Yun Kim, Miri Kim, Dong Il Kim, Hyeon-Ah Kim, Arie Kim, Esther Kim, Ok-Hwa Kim, Sun-Hee Kim, Juyong B Kim, Joong-Seok Kim, Jong Woo Kim, Saerom Kim, Wondong Kim, Seong-Hyun Kim, Misung Kim, Min Wook Kim, Dong-Ik Kim, Minsuk Kim, Hyung-Jun Kim, Ohn Soon Kim, Sung Han Kim, Jae Hyun Kim, Sewoon Kim, Sung Tae Kim, Richard Kim, Albert H Kim, Ju Deok Kim, Jin Seok Kim, Chong Ae Kim, Hyun-Ji Kim, Yong Kyung Kim, Eunju Kim, Yun Hye Kim, Sun-Hong Kim, Soyeong Kim, Sowon Kim, Young Sik Kim, Jisun Kim, Mi-Hyun Kim, Haein Kim, Byung-Gyu Kim, Jeonghan Kim, JongKyong Kim, Jin Young Kim, So Ree Kim, Hee Jin Kim, Minjae Kim, Hyun Kim, Kyoung Oh Kim, Jiyea Kim, Jun Hoe Kim, Joon Kim, Sunghwan Kim, Bo-Rahm Kim, Namkyoung Kim, Hee Jeong Kim, Aram Kim, Youn-Jung Kim, Joung Sug Kim, Kangjoon Kim, Hail Kim, Younghoon Kim, Eui Jin Kim, Cheol-Su Kim, Jae Geun Kim, Min Kyeong Kim, Ngoc Thanh Kim, Seong-Seop Kim, Ji-Man Kim, Ju-Kon Kim, Hyeong-Taek Kim, Soo Wan Kim, Woong-Ki Kim, Ju-Wan Kim, Sunggun Kim, Kevin K Kim, Sun Woong Kim, Soeun Kim, Jin Kyong Kim, Hoguen Kim, Sungup Kim, Hyungkuen Kim, Ji Hye Kim, Myoung Hee Kim, Min Ju Kim, Jeong Su Kim, Gwang Sik Kim, Anthony S Kim, Ok Jin Kim, Jeongseop Kim, Bo-Eun Kim, Suk-Kyung Kim, Deok-Ho Kim, Woo-Shik Kim, Sang Soo Kim, Hae Won Kim, Mina K Kim, Kiyoung Kim, Paul H Kim, Taeil Kim, Eun-Kyung Kim, Joonyoung R Kim, Da-Sol Kim, Yeaseul Kim, In Ja Kim, Beomsu Kim, Byungwook Kim, Kyung-Hee Kim, Hyeyoon Kim, Sun Yeou Kim, Hyojin Kim, Jongmyung Kim, Yangseok Kim, Jong Ho Kim, Chunki Kim, Seokjoong Kim, Helen Kim, Sungyeon Kim, Mi Ra Kim, Dae-Eun Kim, Young-Dae Kim, Young Mi Kim, Na-Kuang Kim, Yoon Sook Kim, Jayoun Kim, Byoung Jae Kim, Jung Dae Kim, Joseph Han Sol Kim, Daham Kim, Mijung Kim, Yu Kyeong Kim, Yong-Lim Kim, E-S Kim, Jin-Chul Kim, Chan Wook Kim, Hyeong-Jin Kim, Boo-Young Kim, Sang Hyuk Kim, Sung-Mi Kim, Dongwoo Kim, Seul-Ki Kim, Hye Jin Kim, Gibae Kim, Soo Young Kim, Sang Ryong Kim, Sukjun Kim, Dong Joon Kim, Hyo Jung Kim, Yeseul Kim, Jieun Kim, Jongchan Kim, Joseph C Kim, Yong Sik Kim, Nam-Eun Kim, Jun Pyo Kim, Sang-Tae Kim, Brandon J Kim, Hong Sug Kim, Youngjoo Kim, Sun-Gyun Kim, Min-Gon Kim, Young-Woo Kim, Myungshin Kim, Tae Hoen Kim, Soon Hee Kim, Won Kim, Chanhee Kim, Jung Oh Kim, Jun-Sik Kim, Ji Eun Kim, Hyun-Kyong Kim, Jeffrey Kim, Yeonhwa Kim, Jung-In Kim, Chan-Wha Kim, B-Y Kim, B T Kim, Dahee Kim, Taek-Yeong Kim, Yeon Ju Kim, Duck-Hee Kim, Hyunjoon Kim, Young-Saeng Kim, Seohyeon Kim, Soon Sun Kim, Hyeon Jeong Kim, Jae Bum Kim, Yeul Hong Kim, Hyemin Kim, Shin Kim, Juhyun Kim, Chang-Gu Kim, Y S Kim, Dan Say Kim, Ji-Dam Kim, Gwangil Kim, Alison J Kim, Paul T Kim, Kyoung Hoon Kim, Hwa-Jung Kim, Ye-Ri Kim, Youngeun Kim, Cheol-Hee Kim, Hee-Jin Kim, Jason Kim, Youngsin Kim, NamHee Kim, Hyuk Soon Kim, Byung-Chul Kim, Cecilia Kim, S Kim, Tae-Gyu Kim, Kwan-Suk Kim, Seung-Ki Kim, Jee Ah Kim, Moon Suk Kim, Young Ju Kim, Kyoungtae Kim, Yunwoo Kim, J Y Kim, Lia Kim, Soo-Hyun Kim, Byung Jin Kim, You-Sun Kim, Seong Jun Kim, Youngsoo Kim, Yunkyung Kim, Mi Jeong Kim, Myoung Sook Kim, Meelim Kim, Kye-Seong Kim, Chu-Young Kim, Minseon Kim, Minsu Kim, Hye-Jin Kim, Il-Man Kim, Seong-Tae Kim, Dong Ha Kim, Soo Yoon Kim, Donghyeon Kim, Sunoh Kim, Yu-Jin Kim, Yul-Ho Kim, Stuart K Kim, Eric Kim, Soo Hyun Kim, Jae-Young Kim, Jin Hee Kim, Tae Min Kim, Il-Chan Kim, Mi-Na Kim, Yeji Kim, Yo-Han Kim, Yeong-Sang Kim, Eunmi Kim, Taewan Kim, Kyong-Tai Kim, Dae-Kyeong Kim, Yun Seok Kim, Kyung Hee Kim, M Kim, June Hee Kim, Hyun Eun Kim, Eunkyeong Kim, Tae Hyun Kim, Soee Kim, Young-Im Kim, So-Hee Kim, Hyeong Hoe Kim, Hee Young Kim, Leo A Kim, Eungseok Kim, Sungyun Kim, Young S Kim, Min Bum Kim, Min Seo Kim, Tae-You Kim, Jong-Yeon Kim, Tae Hoon Kim, Sungrae Kim, Eun-Jin Kim, Heejin Kim, Tae Jin Kim, Seong-Jin Kim, Young-Chul Kim, Jinkyeong Kim, SooHyeon Kim, Ju Young Kim, Kwangwoo Kim, Un-Kyung Kim, Dong-Hee Kim, Sang Wun Kim, Jin Woo Kim, Gu-Hwan Kim, Young-Mi Kim, Dae-Kyum Kim, Won J Kim, Seung Won Kim, Tae-Min Kim, Seon-Kyu Kim, Hana Kim, Hye Ran Kim, Ji-Yul Kim, Moo-Yeon Kim, Do Yeon Kim, Jun Seok Kim, Su-Jin Kim, Yuli Kim, Jung Ho Kim, Edwin H Kim, Jewoo Kim, A Ram Kim, Grace Kim, Jongho Kim, Hyung Hoi Kim, Soung Jung Kim, Song-Rae Kim, Jinsup Kim, Dong-Kyu Kim, Su-Hyeong Kim, Hye-Ran Kim, Kee-Tae Kim, Nam-Ho Kim, Yoongeum Kim, Jeong-Han Kim, Jin Gyeom Kim, Jinsoo Kim, Mi Young Kim, Hyun-Sic Kim, Steve Kim, Kyung-Sup Kim, Taeyoung Kim, Hyeonwoo Kim, Dong Gwang Kim, Jong-Youn Kim, Hwi Seung Kim, Doo Yeon Kim, Hye Ree Kim, Hyeong-Geug Kim, Jong-Il Kim, Soo Whan Kim, Kwang-Eun Kim, Jong-Won Kim, Eung-Gook Kim, Jaehoon Kim, Yu Mi Kim, J H Kim, Hyoung Kyu Kim, Hark Kyun Kim, Suk Jae Kim, Sung-Hee Kim, Jonggeol J Kim, Sang Eun Kim, Na-Young Kim, Minji Kim, Jeong Kyu Kim, Jongkyu Kim, Jae-Yoon Kim, Hyunjin Kim, Eun Ji Kim, Youngmi Kim, William Kim, Helen B Kim, Jiho Kim, Dae In Kim, Dennis Y Kim, Sunghun Kim, Nari Kim, Doyeon Kim, Sang-Min Kim, Dong-Yi Kim, Myeong-Kyu Kim, Youngsook Kim, Ji-Yun Kim, Sung Woo Kim, Ha-Jung Kim, Yongmin Kim, Angela H Kim, Han Young Kim, Hye-Jung Kim, Hyun-Soo Kim, Hyunju Kim, Jin Man Kim, Hyung-Suk Kim, Young Nam Kim, Hang-Rai Kim, Hyoun-Ah Kim, Hye Young Kim, Sung-Wan Kim, Sung Yeol Kim, Jong-Oh Kim, Y-D Kim, Jong-Hyun Kim, Myung-Sun Kim, Jenny H Kim, Youngchang Kim, Mi Kyung Kim, Eun Young Kim, Okhwa Kim, Jinhee Kim, Y A Kim, Won Kyung Kim, Hyung-Gu Kim, Dongjoon Kim, Woo Sik Kim, Myung Jin Kim, In Suk Kim, Hannah Kim, Ick Young Kim, Hyunsoo Kim, Sung Eun Kim, Yekaterina Kim, Sungjoo Kim, Seonhee Kim, Y-M Kim, Sun Hee Kim, Juyoung Kim, Jung Sun Kim, Ji Young Kim, Hong-Hee Kim, Hye-Sung Kim, Sung-Eun Kim, Wun-Jae Kim, Ji Hyun Kim, Kyung Mee Kim, Hee Nam Kim, Sunghak Kim, Dong-Hoon Kim, Vladimir Kim, Yong-Wan Kim, Seul Young Kim, Myoung Ok Kim, Jong-Seok Kim, H Kim, Minsik Kim, Sang-Young Kim, Donghee Kim, June-Bum Kim, Dong Hyun Kim, Sang Jin Kim, Jihoon Kim, Won Ho Kim, Byeong-Won Kim, Jaegil Kim, Hyung-Goo Kim, Tae Wan Kim, Seonggon Kim, J Julie Kim, Jiwon Kim, Eun-Joo Kim, Seongho Kim, Hyun Soo Kim, Dong Wook Kim, Tae-Hyoung Kim, Anna Kim, Gahyun Kim, Jun-Hyung Kim, Don-Kyu Kim, Jong Hwan Kim, Kyung An Kim, Jun Suk Kim, Borahm Kim, Caroline Kim, Andrea J Kim, Jung-Lye Kim, Yong-Hoon Kim, Dongkyun Kim, Sung Kyun Kim, Jisup Kim, Yong Kyun Kim, Yerin Kim, Young-Eun Kim, Seung Woo Kim, Jun W Kim, Angela Kim, Eunae Kim, Tae-Eun Kim, Won Tae Kim, Kyung-Sub Kim, Ji Won Kim, Sang Geon Kim, Kang Ho Kim, Young-Cho Kim, Chul Hwan Kim, Bo Young Kim, Yong Sig Kim, Hong-Kyu Kim, Go Woon Kim, Minsoon Kim, Peter K Kim, Taeeun Kim, Eunhyun Kim, Min-Sik Kim, Paul Kim, Jeongseon Kim, Hyejin Kim, Chang-Yub Kim, Kyunggon Kim, Sinai Kim, Tae-Mi Kim, Oc-Hee Kim, Da-Hyun Kim, Jong Geun Kim, Woo Kyung Kim, Jae-Yong Kim, Jiyeon Kim, Jaeuk U Kim, Kye Hyun Kim, Dae-Jin Kim, Chong Kook Kim, Minkyung Kim, Jun Chul Kim, Cecilia E Kim, Jae Seon Kim, Yeon-Jeong Kim, Ha-Neui Kim, Kwan Hyun Kim, Dae Keun Kim, You Sun Kim, Heung-Joong Kim, Jongwan Kim, Angela S Kim, Young Hun Kim, Nam Hee Kim, Jong Yeol Kim, Ji-Young Kim, So-Woon Kim, Dayoung Kim, Sangwoo Kim, Ji-Hoon Kim, Ki Tae Kim, Young-Bum Kim, Eric Eunshik Kim, Hyojung Kim, Yeeun Kim, Jeewoo Kim, Sungmin Kim, Hyun Sil Kim, Young Hee Kim, Woonhee Kim, Minjeong Kim, Sae Hun Kim, Sohee Kim, Kyunga Kim, Donghyun Kim, Sung-Kyu Kim, Hanah Kim, Do-Kyun Kim, Jong-Joo Kim, Sangsoo Kim, Yong-Woon Kim, Jonggeol Jeffrey Kim, Geun-Young Kim, Jae-Jun Kim, Min Soo Kim, K-K Kim, Jung-Taek Kim, Ju Han Kim, Jeeyoung Kim, Hyung Yoon Kim, Min-Sun Kim, Youngchul Kim, Minhee Kim, Byung-Taek Kim, Sung-Bae Kim, Kwang Pyo Kim, Suk-Jeong Kim, Min-A Kim, Ngoc-Thanh Kim, Jae T Kim, Chan-Duck Kim, Dong-Seok Kim, Hyeon Ho Kim, Soo-Youl Kim, Min-Seon Kim, Young Tae Kim, Hyoun Ju Kim, Shi-Mun Kim, Kwang-Pyo Kim, Hee Jong Kim, JungMin Kim, Minah Kim, Taehyoun Kim, Kwonseop Kim, Yonghwan Kim, Kyong Min Kim, Won Dong Kim, Su-Jeong Kim, Jae-Jung Kim, Eunha Kim, Howard H Kim, Min-Hyun Kim, Kyeongjin Kim, Min Kim, Sung Won Kim, Min-Seo Kim, Se-Wha Kim, Myeoung Su Kim, Minjoo Kim, Sujung Kim, Eonmi Kim, In-Hoo Kim, Woo-Kyun Kim, Nan Young Kim, Myeong Ok Kim, Yongjae Kim, Wootae Kim, Jong-Kyu Kim, In Kyoung Kim, Leen Kim, Doo Yeong Kim, Do-Hyung Kim, Dong-il Kim, Jeri Kim, Dong-Hyeok Kim, Seol-A Kim, Soriul Kim, Kil-Nam Kim, Joonseok Kim, Soo-Rim Kim, So Yeon Kim, Kwangho Kim, Yun-Jin Kim, Yeonjung Kim, Seok Won Kim, Bo Ri Kim, Su Jin Kim, TaeHyung Kim, Kyung Woo Kim, Woo Jin Kim, Yeon-Jung Kim, Misun Kim, Serim Kim, Jeong Hee Kim, Youn Shic Kim, Junesun Kim, Dong-Eun Kim, Young Ree Kim, So-Yeon Kim, Choel Kim, Jae Hun Kim, C H Kim, Sung-Hoon Kim, Namphil Kim, Kyung-Chang Kim, Jin-Soo Kim, Jimi Kim, You-Jin Kim, Goun Kim, Goo-Young Kim, Chan-Hee Kim, Jong Han Kim, Bongjun Kim, Sun-Joong Kim, Sun Hye Kim, Seulhee Kim, Joonyoung Kim, Gunhee Kim, Joungmok Kim, Young Ho Kim, Seung-Whan Kim, Sang-Woo Kim, Seongmi Kim, Kyung Sup Kim, Young Jin Kim, Scott Y H Kim, Chang Seong Kim, Ryung S Kim, Daegyeom Kim, Da Sol Kim, Ellen Kim, Kellan Kim, Young Rae Kim, Hee-Sun Kim, Seung Jun Kim, Han Gyung Kim, Jae Hoon Kim, Kyungjin Kim, Youn-Kyung Kim, Jung-Ha Kim, Sunghoon Kim, Jung-Hyun Kim, Jaeyeon Kim, Hyung-Mi Kim, Young Eun Kim, Hye-Young H Kim, Ho Shik Kim, Ho-Sook Kim, Hyun Ju Kim, Hwijin Kim, Gyeonghun Kim, Kyungtae Kim, Baek Kim, Soon-Hee Kim, David E Kim, Ki Kwon Kim, Joong Sun Kim, Yongae Kim, Jaemi Kim, Hyun-ju Kim, Tai Kyoung Kim, Hoon Seok Kim, Yunjung Kim, Keun You Kim, Se Hyun Kim, Min Cheol Kim, Gye Lim Kim, Hyeseon Kim, Jin Cheon Kim, Hyung-Ryong Kim, Carla F Kim, Hyunki Kim, Dakyung Kim, Yong-Sik Kim, Jong Won Kim, Hoon Kim, Seung-Jin Kim, Myeong Ji Kim, Joonki Kim, NamDoo Kim, Jinho Kim, Hyo Jong Kim, Young-Woong Kim, Un Gi Kim, Tae-Hyun Kim, Hyung-Sik Kim, Ah-Ram Kim, Kee-Pyo Kim, Oh Yoen Kim, Juyeong Kim, Deok Ryong Kim, Jun Hee Kim, Hyunyoung Kim, Jung Ki Kim, Yongkang Kim, Chae-Hyun Kim, Brian S Kim, Minchul Kim, Leo Kim, Eun Ho Kim, Haeryoung Kim, Seong Kim, Jessica Kim, Kahye Kim, Jae-Ryong Kim, Jin Won Kim, Hyun Sook Kim, Kyeongmi Kim, Rosalind Kim, Heegoo Kim, Sujin Kim, In Joo Kim, E Kim, Sung-Jo Kim, Sang Chan Kim, Kyuho Kim, Nam-Hyung Kim, Sin Gon Kim, Sunkyu Kim, Seohyun Kim, Beom-Jun Kim, Boram Kim, Kyeong Jin Kim, Wanil Kim, Gi Beom Kim, Hei Sung Kim, Jason K Kim, Woojin Scott Kim, Hyung-Seok Kim, Won Jeoung Kim, Jungwoo Kim, Dae Hyun Kim, Yejin Kim, Jina Kim, Kyu-Kwang Kim, Yong-Soo Kim, Yong-Ou Kim, M J Kim, Ji-Won Kim, Yoonjung Kim, Chul Hoon Kim, Hyun-Jung Kim, Jae Hyoung Kim, Eui-Soon Kim, Hyun Joon Kim, Minkyeong Kim, M V Kim, Hyun-Jin Kim, Ok-Kyung Kim, Yumi Kim, Kyungsook Kim, Kyungwon Kim, Sunyoung Kim, Jin Kim, Suji Kim, Ok-Hyeon Kim, Maya Kim, Mijeong Kim, Jung-Woong Kim, Seoyeon Kim, Hyunbae Kim, Esl Kim, Kyeong-Min Kim, Sang-Hoon Kim, Hyun Gi Kim, Jooho Kim, Su Kang Kim, Ju-Ryoung Kim, Myung-Jin Kim, Eun-Jung Kim, Sangchul Kim, Bomi Kim, Kyung Han Kim, Seoyoung Kim, Ji-Eun Kim, Yoojin Kim, Joori Kim, Min Jung Kim, Minju Kim, Jeeho Kim, Tae-Woon Kim, Jihye Kim, Jae Gon Kim, Hyeong Su Kim, Choon-Song Kim, Kye Hun Kim, Mi-Young Kim, Choon Ok Kim, Hyesung Kim, Na Yeon Kim, Seong-Ik Kim, Yeon-Ki Kim, Jisu Kim, Jaeyoon Kim, Dong-Hyun Kim, Myungsuk Kim, Kook Hwan Kim, Eui Hyun Kim, Won-Tae Kim, Sung Soo Kim, Sung Hyun Kim, Eun Kim, Hyung Min Kim, Sol Kim, Jihyun Kim, Hyunwoo Kim, Kwang Dong Kim, Min Joo Kim, Suhyun Kim, Elizabeth H Kim, Sang-Gun Kim, Han-Kyul Kim, Dong-Wook Kim, Young Sam Kim, Yong Deuk Kim, Jong-Seo Kim, Young-Ho Kim, Yoo Ri Kim, Hye-Yeon Kim, Eiru Kim, Ji Yeon Kim, Ki Hyun Kim, Tae Hun Kim, Ae-Jung Kim, Yun Joong Kim, Eosu Kim, Ki Woong Kim, Cheorl-Ho Kim, TaeYeong Kim, Yeon-Hee Kim, Jae Suk Kim, Richard B Kim, Jungsu Kim, Young-Jin Kim, Deokhoon Kim, Eung Yeop Kim, Misu Kim, Seung Chul Kim, Mi-Yeon Kim, K-S Kim, Hyo-Soo Kim, Daeseung Kim, Won Kon Kim, Sangmi Kim, Jong Deog Kim, Yun Gi Kim, Seon-Young Kim, Il-Sup Kim, Ji Hun Kim, Byung Guk Kim, Susy Kim, Youngwoo Kim, Mi-Sung Kim, Min-Young Kim, Jae-Min Kim, Young Woo Kim, Yong Sung Kim, Young-Won Kim, Taehyeung Kim, Meesun Kim, Sook Young Kim, Jaewon Kim, Jung H Kim, In Su Kim, Eun Hee Kim, Yong Kwan Kim, Haelee Kim, Daesik Kim, Heebal Kim, Seungsoo Kim, Bong-Jo Kim, Woo-Jin Kim, Seon Hwa Kim, Luke Y Kim, Jae-Ick Kim, Hwajung Kim, Jisook Kim, Jeffrey J Kim, Kyung Do Kim, Gukhan Kim, Jungeun Kim, Youbin Kim, Jeong-Min Kim, Hyungjun Kim, Young-Hoon Kim, Seokhwi Kim, Jong-Ki Kim, Byron Kim, Taek-Kyun Kim, D-W Kim, Bo-Ra Kim, Dokyoon Kim, Su-Yeon Kim, Min Chul Kim, Jung Hee Kim, Wook Kim, Jun-Mo Kim, Miso Kim, Seong-Min Kim, Jang Heub Kim, Seon Hee Kim, Hong-Gi Kim, Hyun-Young Kim, Young Hwa Kim, Hyeyoung Kim, Hyunwook Kim, Hyung Bum Kim, Dae-Soo Kim, Hee Su Kim, Gitae Kim, Hyun-Yi Kim, Sejoong Kim, Young-Joo Kim, Reuben H Kim, Hong-Kook Kim, Hyungsoo Kim, Soo Jung Kim, Sungryong Kim, Hyunmi Kim, June Soo Kim, Gyudong Kim, Rokki Kim, Yong Sook Kim, Young-Il Kim, Jinsu Kim, Woo-Yang Kim, Eunjoon Kim, Taejung Kim, Woo Kim, Jang-Hee Kim, Won Seok Kim, Jung Soo Kim, Kyoung Hwan Kim, Sung Mok Kim, Seung Tea Kim, Tae Il Kim, Daeeun Kim, Hyelim Kim, Beomsoo Kim, Ji-Woon Kim
To describe the phenotype of CLN-associated retinal dystrophy in a subset of patients at the Columbia University Medical Center, United States, and the Hospital das Clínicas de Pernambuco, Brazil, in Show more
To describe the phenotype of CLN-associated retinal dystrophy in a subset of patients at the Columbia University Medical Center, United States, and the Hospital das Clínicas de Pernambuco, Brazil, in comparison to the published literature. Eleven patients with confirmed biallelic variants in the CLN genes were evaluated via dilated fundus examination, clinical imaging, and full-field electroretinogram. A thorough literature search was conducted to determine previously published variants and associated phenotypes. Genetic testing confirmed the presence of variants in CLN3, CLN7/MFSD8, CLN8, and GRN/CLN11. Five novel variants were identified, and four novel phenotypes of previously published alleles were described. The phenotype differed among patients with variants in the same gene and sometimes among patients with the same allele. Substantial phenotypic variability among variants in the CLN genes makes identification of genotype-phenotype or allele-phenotype correlations challenging. Further study is required to establish an extensive database for adequate patient counseling. Show less
The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemot Show more
The glucocorticoid receptor (GR) is an important anti-cancer target in lymphoid cancers but has been understudied in solid tumors like lung cancer, although glucocorticoids are often given with chemotherapy regimens to mitigate side effects. Here, we identify a dexamethasone-GR mediated anti-cancer response in a subset of aggressive non-small cell lung cancers (NSCLCs) that harbor Serine/Threonine Kinase 11 (STK11/LKB1) mutations. High tumor expression of carbamoyl phosphate synthase 1 (CPS1) was strongly linked to the presence of LKB1 mutations, was the best predictor of NSCLC dexamethasone (DEX) sensitivity ( Show less
Cancer cell heterogeneity is a serious problem in the control of tumor progression because it can cause chemoresistance and metastasis. Heterogeneity can be generated by various mechanisms, including Show more
Cancer cell heterogeneity is a serious problem in the control of tumor progression because it can cause chemoresistance and metastasis. Heterogeneity can be generated by various mechanisms, including genetic evolution of cancer cells, cancer stem cells (CSCs), and niche heterogeneity. Because the genetic heterogeneity of CSCs has been poorly characterized, the genetic mutation status of CSCs was examined using Exome-Seq and RNA-Seq data of liver cancer. Here we show that different surface markers for liver cancer stem cells (LCSCs) showed a unique propensity for genetic mutations. Cluster of differentiation 133 (CD133)-positive cells showed frequent mutations in the Show less
Cultured human pluripotent stem cells (hPSCs) grow as colonies that require breakdown into small clumps for further propagation. Although cell death mechanism by single-cell dissociation of hPSCs has Show more
Cultured human pluripotent stem cells (hPSCs) grow as colonies that require breakdown into small clumps for further propagation. Although cell death mechanism by single-cell dissociation of hPSCs has been well defined, how hPSCs respond to the deadly stimulus and recover the original status remains unclear. Here we show that dissociation of hPSCs immediately activates ERK, which subsequently activates RSK and induces DUSP6, an ERK-specific phosphatase. Although the activation is transient, DUSP6 expression persists days after passaging. DUSP6 depletion using the CRISPR/Cas9 system reveals that DUSP6 suppresses the ERK activity over the long term. Elevated ERK activity by DUSP6 depletion increases both viability of hPSCs after single-cell dissociation and differentiation propensity towards mesoderm and endoderm lineages. These findings provide new insights into how hPSCs respond to dissociation in order to maintain pluripotency. Show less
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide associatio Show more
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study of lung adenocarcinoma of East Asian ancestry (21,658 cases and 150,676 controls; 54.5% never-smokers) and identified 12 novel susceptibility variants, bringing the total number to 28 at 25 independent loci. Transcriptome-wide association analyses together with colocalization studies using a Taiwanese lung expression quantitative trait loci dataset (n = 115) identified novel candidate genes, including FADS1 at 11q12 and ELF5 at 11p13. In a multi-ancestry meta-analysis of East Asian and European studies, four loci were identified at 2p11, 4q32, 16q23, and 18q12. At the same time, most of our findings in East Asian populations showed no evidence of association in European populations. In our studies drawn from East Asian populations, a polygenic risk score based on the 25 loci had a stronger association in never-smokers vs. individuals with a history of smoking (P Show less
A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with mult Show more
A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with multiple nodules on the right hepatic medial lobe adjacent to the caudal Show less
Over 90% of the U.S. adult population suffers from tooth structure loss due to caries. Most of the mineralized tooth structure is composed of dentin, a material produced and mineralized by ectomesench Show more
Over 90% of the U.S. adult population suffers from tooth structure loss due to caries. Most of the mineralized tooth structure is composed of dentin, a material produced and mineralized by ectomesenchyme derived cells known as odontoblasts. Clinicians, scientists, and the general public share the desire to regenerate this missing tooth structure. To bioengineer missing dentin, increased understanding of human tooth development is required. Here we interrogate at the single cell level the signaling interactions that guide human odontoblast and ameloblast development and which determine incisor or molar tooth germ type identity. During human odontoblast development, computational analysis predicts that early FGF and BMP activation followed by later HH signaling is crucial. Application of this sci-RNA-seq analysis generates a differentiation protocol to produce mature hiPSC derived odontoblasts Show less
Ovarian cancer is the leading cause of death among gynecologic cancers. Paclitaxel is used as a standard first-line therapeutic agent for ovarian cancer. However, chemotherapeutic resistance and high Show more
Ovarian cancer is the leading cause of death among gynecologic cancers. Paclitaxel is used as a standard first-line therapeutic agent for ovarian cancer. However, chemotherapeutic resistance and high recurrence rates are major obstacles to treating ovarian cancer. We have found that tephrosin, a natural rotenoid isoflavonoid, can resensitize paclitaxel-resistant ovarian cancer cells to paclitaxel. Cell viability, immunoblotting, and a flow cytometric analysis showed that a combination treatment made up of paclitaxel and tephrosin induced apoptotic death. Tephrosin inhibited the phosphorylation of AKT, STAT3, ERK, and p38 MAPK, all of which simultaneously play important roles in survival signaling pathways. Notably, tephrosin downregulated the phosphorylation of FGFR1 and its specific adapter protein FRS2, but it had no effect on the phosphorylation of the EGFR. Immunoblotting and a fluo-3 acetoxymethyl assay showed that tephrosin did not affect the expression or function of P-glycoprotein. Additionally, treatment with N-acetylcysteine did not restore cell cytotoxicity caused by a treatment combination made up of paclitaxel and tephrosin, showing that tephrosin did not affect the reactive oxygen species scavenging pathway. Interestingly, tephrosin reduced the expression of the anti-apoptotic factor XIAP. This study demonstrates that tephrosin is a potent antitumor agent that can be used in the treatment of paclitaxel-resistant ovarian cancer via the inhibition of the FGFR1 signaling pathway. Show less
Fetal bovine serum (FBS), which contains various nutrients, comprises 20% of the growth medium for cell-cultivated meat. However, ethical, cost, and scientific issues, necesitates identification of al Show more
Fetal bovine serum (FBS), which contains various nutrients, comprises 20% of the growth medium for cell-cultivated meat. However, ethical, cost, and scientific issues, necesitates identification of alternatives. In this study, we investigated commercially manufactured serum-free media capable of culturing Hanwoo satellite cells (HWSCs) to identify constituent proliferation enhancing factors. Six different serum-free media were selected, and the HWSC proliferation rates in these serum-free media were compared with that of control medium supplemented with 20% FBS. Among the six media, cell proliferation rates were higher only in StemFlex Show less
Although VEGF-B was discovered as a VEGF-A homolog a long time ago, the angiogenic effect of VEGF-B remains poorly understood with limited and diverse findings from different groups. Notwithstanding, Show more
Although VEGF-B was discovered as a VEGF-A homolog a long time ago, the angiogenic effect of VEGF-B remains poorly understood with limited and diverse findings from different groups. Notwithstanding, drugs that inhibit VEGF-B together with other VEGF family members are being used to treat patients with various neovascular diseases. It is therefore critical to have a better understanding of the angiogenic effect of VEGF-B and the underlying mechanisms. Using comprehensive in vitro and in vivo methods and models, we reveal here for the first time an unexpected and surprising function of VEGF-B as an endogenous inhibitor of angiogenesis by inhibiting the FGF2/FGFR1 pathway when the latter is abundantly expressed. Mechanistically, we unveil that VEGF-B binds to FGFR1, induces FGFR1/VEGFR1 complex formation, and suppresses FGF2-induced Erk activation, and inhibits FGF2-driven angiogenesis and tumor growth. Our work uncovers a previously unrecognized novel function of VEGF-B in tethering the FGF2/FGFR1 pathway. Given the anti-angiogenic nature of VEGF-B under conditions of high FGF2/FGFR1 levels, caution is warranted when modulating VEGF-B activity to treat neovascular diseases. Show less
Protein tyrosine kinase 7 (PTK7), a catalytically defective receptor tyrosine kinase (RTK), is often upregulated in various cancers. This study aimed to validate PTK7 as a target for breast cancer (BC Show more
Protein tyrosine kinase 7 (PTK7), a catalytically defective receptor tyrosine kinase (RTK), is often upregulated in various cancers. This study aimed to validate PTK7 as a target for breast cancer (BC) and investigate its oncogenic signaling mechanism. BC tissue analysis showed significantly elevated PTK7 mRNA levels, especially in refractory triple-negative breast cancer (TNBC) tissues, compared with normal controls. Similarly, BC cell lines exhibited increased PTK7 expression. Knockdown of PTK7 inhibited the proliferation of T-47D and MCF-7 hormone-receptor-positive BC cell-lines and of HCC1187, MDA-MB-231, MDA-MB-436, and MDA-MB-453 TNBC cells. PTK7 knockdown also inhibited the adhesion, migration, and invasion of MDA-MB-231, MDA-MB-436, and MDA-MB-453 cells, and reduced the phosphorylation levels of crucial oncogenic regulators including extracellular signal-regulated kinase (ERK), Akt, and focal adhesion kinase (FAK). Furthermore, PTK7 interacts with fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR) expressed in MDA-MB-231 cells. Knockdown of PTK7 decreased the growth-factor-induced phosphorylation of FGFR1 and EGFR in MDA-MB-231 cells, indicating its association with RTK activation. In conclusion, PTK7 plays a significant role in oncogenic signal transduction by enhancing FGFR1 and EGFR activation, influencing BC tumorigenesis and metastasis. Hence, PTK7 represents a potential candidate for targeted BC therapy, including TNBC. Show less
This study reports on diffuse leptomeningeal glioneuronal tumor (DL-GNT) in a 29-year-old male. DL-GNT is a rare central nervous system (CNS) tumor mostly seen in children and only few cases have been Show more
This study reports on diffuse leptomeningeal glioneuronal tumor (DL-GNT) in a 29-year-old male. DL-GNT is a rare central nervous system (CNS) tumor mostly seen in children and only few cases have been reported in adult patients. Our patient presented with a chronic headache that lasted for five months. MR imaging showed mild hydrocephalus, multiple rim-enhancing nodular lesions in the suprasellar cistern, diffuse leptomeningeal enhancement in the lumbosacral area, and multiple small non-enhancing cyst-appearing lesions not suppressed on fluid attenuated inversion recovery (FLAIR) images in the bilateral basal ganglia, thalami, and cerebral hemispheres. Under the impression of germ cell tumor with leptomeningeal seeding, the patient underwent trans-sphenoidal tumor removal. DL-GNT was pathologically confirmed and FGFR1 mutation was detected through a next-generation sequencing test. In conclusion, a combination of leptomeningeal enhancement and multiple parenchymal non-enhancing cyst-appearing lesions not suppressed on FLAIR images may be helpful for differential diagnosis despite overlapping imaging features with many other CNS diseases that have leptomeningeal enhancement. Show less
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced levels of antivir Show more
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced levels of antiviral proteins (AVPs) and circadian regulators, including Bmal1 and Clock. Bmal1 and Clock were found to control rhythmic AVP expression in skin, and such circadian control of AVPs was diminished by disruption of immune cell IL-27 signaling and deletion of Bmal1/Clock genes in mouse skin, as well as siRNA-mediated knockdown of CLOCK in human primary keratinocytes. We found that treatment with the circadian-enhancing agents nobiletin and SR8278 reduced infection of herpes simplex virus 1 in epidermal explants and human keratinocytes in a BMAL1/CLOCK-dependent manner. Circadian-enhancing treatment also reversed susceptibility of aging murine skin and human primary keratinocytes to viral infection. These findings reveal an evolutionarily conserved and age-sensitive circadian regulation of cutaneous antiviral immunity, underscoring circadian restoration as an antiviral strategy in aging populations. Show less
Allium cepa L. (A. cepa) is one of the oldest cultivated plants in the world. A. cepa has been used in traditional folk medicine to treat inflammatory disease in several regions, such as Palestine and Show more
Allium cepa L. (A. cepa) is one of the oldest cultivated plants in the world. A. cepa has been used in traditional folk medicine to treat inflammatory disease in several regions, such as Palestine and Serbia. A. cepa peel has a higher content of flavonoids, such as quercetin, than the edible parts. These flavonoids alleviate inflammatory diseases. However, the anti-inflammatory effects of A. cepa peel extract-obtained using various extraction methods-and their underlying mechanisms require further investigation. Although research to find safe anti-inflammatory substances in various natural products has been actively conducted for many years, it is important to continue identifying potential anti-inflammatory effects in natural materials. The purpose of this study was to investigate the ethnopharmacological properties of the A. cepa peel extract, whose efficacy when obtained through different extraction methods and underlying action mechanisms is not well known. The present study specifically aimed to observe the anti-inflammatory effects of the A. cepa peel extracts obtained using various extraction methods and the related detailed mechanisms of A. cepa peel extracts in lipopolysaccharide (LPS)-induced RAW264.7 cells. The total flavonoid content of the A. cepa peel extracts was determined the diethylene glycol colorimetric method and measured using a calibration curve prepared using quercetin as a standard solution. The antioxidant activity was evaluated using the ABTS assay, and cytotoxicity was measured using the MTT assay. NO production was measured using Griess reagent. Protein levels were measured by western blotting, and mRNA expression was measured by RT-qPCR. Secreted cytokines were analyzed using ELISA or cytokine arrays. In the GSE160086 dataset, we calculated Z-scores for individual genes of interest and displayed using a heat map. Of the three A. cepa peel extracts obtained using different extraction methods, the A. cepa peel 50% EtOH extract (AP50E) was the most effective at inhibiting LPS-induced nitric oxide (NO) and inducible nitric oxide synthase (iNOS). Furthermore, AP50E significantly reduced the levels of pro-inflammation cytokines interleukin (IL)-1α, IL-1β, IL-6, and IL-27. Additionally, AP50E directly inhibited the Janus kinase-signaling transducer and activator of transcription (JAK-STAT) pathway. These results showed that AP50E exhibited an anti-inflammatory effect in LPS-induced RAW264.7 mouse macrophages by directly inhibiting JAK-STAT signaling. Based on these findings, we propose AP50E as a potential candidate for the development of preventive or therapeutic agents against inflammatory diseases. Show less
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced antiviral protein Show more
Aged skin is prone to viral infections, but the mechanisms responsible for this immunosenescent immune risk are unclear. We observed that aged murine and human skin expressed reduced antiviral proteins (AVPs) and circadian regulators including Bmal1 and Clock. Bmal1 and Clock were found to control rhythmic AVP expression in skin and such circadian-control of AVPs was diminished by disruption of immune cell interleukin 27 signaling and deletion of Bmal1/Clock genes in mouse skins, as well as siRNA-mediated knockdown of CLOCK in human primary keratinocytes. We found that treatment of circadian enhancing agents, nobiletin and SR8278, reduced infection of herpes simplex virus 1 (HSV1) in epidermal explants and human keratinocytes in a Bmal1/Clock-dependent manner. Circadian enhancing treatment also reversed susceptibility of aging murine skin and human primary keratinocytes to viral infection. These findings reveal an evolutionarily conserved and age-sensitive circadian regulation of cutaneous antiviral immunity, underscoring circadian restoration as an antiviral strategy in aging populations. Show less
IL-27 is an IL-12 family cytokine with immune regulatory properties, capable of modulating inflammatory responses, including autoimmunity. While extensive studies investigated the major target cells o Show more
IL-27 is an IL-12 family cytokine with immune regulatory properties, capable of modulating inflammatory responses, including autoimmunity. While extensive studies investigated the major target cells of IL-27 mediating its functions, the source of IL-27 especially during tissue specific autoimmune inflammation has not formally been examined. IL-27p28 subunit, also known as IL-30, was initially discovered as an IL-27-specific subunit, and it has thus been deemed as a surrogate marker to denote IL-27 expression. However, IL-30 can be secreted independently of Ebi3, a subunit that forms bioactive IL-27 with IL-30. Moreover, IL-30 itself may act as a negative regulator antagonizing IL-27. In this study, we exploited various cell type specific IL-30-deficient mouse models and examined the source of IL-30 in a T cell mediated autoimmune neuroinflammation. We found that IL-30 expressed by infiltrating and CNS resident APC subsets, infiltrating myeloid cells and microglia, is central in limiting the inflammation. However, dendritic cell-derived IL-30 was dispensable for the disease development. Unexpectedly, in cell type specific IL-30 deficient mice that develop severe EAE, IL-30 expression in the remaining wild-type APC subsets is disproportionately increased, suggesting that increased endogenous IL-30 production may be involved in the severe pathogenesis. In support, systemic recombinant IL-30 administration exacerbates EAE severity. Our results demonstrate that dysregulated endogenous IL-30 expression may interfere with immune regulatory functions of IL-27, promoting encephalitogenic inflammation in vivo. Show less
The absence of prominent, actionable genetic alternations in osteosarcomas (OS) implies that transcriptional and epigenetic mechanisms significantly contribute to the progression of this life-threaten Show more
The absence of prominent, actionable genetic alternations in osteosarcomas (OS) implies that transcriptional and epigenetic mechanisms significantly contribute to the progression of this life-threatening form of cancer. Therefore, the identification of potential transcriptional events that promote the survival of OS cells could be key in devising targeted therapeutic approaches for OS. We have previously shown that RUNX2 is a transcription factor (TF) essential for OS cell survival. Unfortunately, the transcriptional network or circuitry regulated by RUNX2 in OS cells is still largely unknown. The TFs that are in the RUNX2 transcriptional circuitry were identified by analyzing RNAseq and ChIPseq datasets of RUNX2. To evaluate the effect of SOX9 knockdown on the survival of osteosarcoma cells in vitro, we employed cleaved caspase-3 immunoblotting and propidium iodide staining techniques. The impact of SOX9 and JMJD1C depletion on OS tumor growth was examined in vivo using xenografts and immunohistochemistry. Downstream targets of SOX9 were identified and dissected using RNAseq, pathway analysis, and gene set enrichment analysis. Furthermore, the interactome of SOX9 was identified using BioID and validated by PLA. Our findings demonstrate that SOX9 is a critical TF that is induced by RUNX2. Both in vitro and in vivo experiments revealed that SOX9 plays a pivotal role in the survival of OS. RNAseq analysis revealed that SOX9 activates the transcription of MYC, a downstream target of RUNX2. Mechanistically, our results suggest a transcriptional network involving SOX9, RUNX2, and MYC, with SOX9 binding to RUNX2. Moreover, we discovered that JMJD1C, a chromatin factor, is a novel binding partner of SOX9, and depletion of JMJD1C impairs OS tumor growth. The findings of this study represent a significant advancement in our understanding of the transcriptional network present in OS cells, providing valuable insights that may contribute to the development of targeted therapies for OS. Show less
Obesity is a known risk factor for metabolic diseases and is often associated with chronic inflammation in adipose tissue. We previously identified the polyethoxylated flavonoid Nobiletin (NOB) as a c Show more
Obesity is a known risk factor for metabolic diseases and is often associated with chronic inflammation in adipose tissue. We previously identified the polyethoxylated flavonoid Nobiletin (NOB) as a circadian clock modulator that directly binds to and activates the ROR receptors in the core oscillator, markedly improving metabolic fitness in obese mice. Here, we show that NOB enhanced the oscillation of core clock genes in differentiated 3T3-L1 adipocytes, including ROR target genes such as Show less
KMT2A (11q23.3) gene rearrangements are found in acute leukemia and are associated with a poor or intermediate prognosis. MLLT10 is the fourth most common gene fusion partner for KMT2A. A reciprocal t Show more
KMT2A (11q23.3) gene rearrangements are found in acute leukemia and are associated with a poor or intermediate prognosis. MLLT10 is the fourth most common gene fusion partner for KMT2A. A reciprocal translocation t(10;11) is insufficient to produce an in-frame KMT2A/MLLT10 fusion, because the genes involved in the rearrangement have opposite transcriptional orientations. In order to bring KMT2A and MLLT10 into juxtaposition, complex rearrangements are required. Until now, conventional chromosome, fluorescence in situ hybridization (FISH), and reverse transcriptase-polymerase chain reaction (RT-PCR) studies have been used to detect KMT2A/MLLT10 fusions. However, conventional studies have limitations, such as poor and inconsistent resolution, when compared to next-generation sequencing (NGS). In this study, we report a pediatric patient with acute megakaryoblastic leukemia, in whom the cryptic KMT2A/MLLT10 fusion was not detected by KMT2A break-apart probe FISH and chromosome analysis, but detected by NGS. In this patient, NGS showed cryptic insertion of MLLT10 exons 9-24 into intron 9 of KMT2A, resulting in a KMT2A/MLLT10 fusion. Therefore, NGS is a valuable complementary option for the evaluation of structural aberrations, especially those with a cryptic size. Show less
Non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes may more easily progress towards severe forms of non-alcoholic steatohepatitis (NASH) and cirrhosis. Although the Wnt effector Show more
Non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes may more easily progress towards severe forms of non-alcoholic steatohepatitis (NASH) and cirrhosis. Although the Wnt effector transcription factor 7-like 2 (TCF7L2) is closely associated with type 2 diabetes risk, the role of TCF7L2 in NAFLD development remains unclear. Here, we investigated how changes in TCF7L2 expression in the liver affects hepatic lipid metabolism based on the major risk factors of NAFLD development. Tcf7l2 was selectively ablated in the liver of C57BL/6N mice by inducing the albumin (Alb) promoter to recombine Tcf7l2 alleles floxed at exon 5 (liver-specific Tcf7l2-knockout [KO] mice: Alb-Cre;Tcf7l2 Alb-Cre;Tcf7l2 In mice, loss of hepatic Tcf7l2 contributes to liver steatosis by inducing preferential metabolism of carbohydrates via DNL activation. Therefore, TCF7L2 could be a promising regulator of the NAFLD associated with high-carbohydrate diets and diabetes since TCF7L2 deficiency may lead to development of NAFLD by promoting utilisation of excess glucose pools through activating DNL. RNA-sequencing data have been deposited into the NCBI GEO under the accession number GSE162449 ( www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162449 ). Show less
Joo Hee Jeong, Yun Gi Kim, Suk-Kyu Oh+19 more · 2023 · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · Oxford University Press · added 2026-04-24
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate th Show more
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate the clinical yield and implications of genetic testing for IVF. This study was based on the multi-centre inherited arrhythmia syndrome registry in South Korea from 2014 to 2017. Next-generation sequencing-based genetic testing was performed that included 174 genes previously linked to cardiovascular disease. A total of 96 patients were clinically diagnosed with IVF. The mean age of the onset was 41.2 ± 12.7 years, and 79 patients were males (82.3%). Of these, 74 underwent genetic testing and four (5.4%) of the IVF probands had pathogenic or likely pathogenic variants (each having one of MYBPC3, MYH7, DSP, and TNNI3). All pathogenic or likely pathogenic variants were located in genes with definite evidence of a cardiomyopathy phenotype, either hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. Next-generation sequencing-based genetic testing identified pathogenic or likely pathogenic variants in 5.4% of patients initially diagnosed with IVF, suggesting that genetic testing with definite evidence genes of cardiomyopathy may enable molecular diagnosis in a minority of patients with IVF. Further clinical evaluation and follow-up of patients with IVF with positive genotypes are needed to unveil concealed phenotypes, such as the pre-clinical phase of cardiomyopathy. Show less
Atherogenesis is an insipidus but precipitating process leading to serious consequences of many cardiovascular diseases (CVD). Numerous genetic loci contributing to atherosclerosis have been identifie Show more
Atherogenesis is an insipidus but precipitating process leading to serious consequences of many cardiovascular diseases (CVD). Numerous genetic loci contributing to atherosclerosis have been identified in human genome-wide association studies, but these studies have limitations in the ability to control environmental factors and to decipher cause/effect relationships. To assess the power of hyperlipidemic Diversity Outbred (DO) mice in facilitating quantitative trait loci (QTL) analysis of complex traits, we generated a high-resolution genetic panel of atherosclerosis susceptible (DO-F1) mouse cohort by crossing 200 DO females with C57BL/6J males carrying two human genes: encoding apolipoprotein E3-Leiden and cholesterol ester transfer protein. We examined atherosclerotic traits including plasma lipids and glucose in the 235 female and 226 male progeny before and after 16 weeks of a high-fat/cholesterol diet, and aortic plaque size at 24 weeks. We also assessed the liver transcriptome using RNA-sequencing. Our QTL mapping for atherosclerotic traits identified one previously reported female-specific QTL on Chr10 with a narrower interval of 22.73 to 30.80 Mb, and one novel male-specific QTL at 31.89 to 40.25 Mb on Chr19. Liver transcription levels of several genes within each QTL were highly correlated with the atherogenic traits. A majority of these candidates have already known atherogenic potential in humans and/or mice, but integrative QTL, eQTL, and correlation analyses further pointed Ptprk as a major candidate of the Chr10 QTL, while Pten and Cyp2c67 of the Chr19 QTL in our DO-F1 cohort. Finally, through additional analyses of RNA-seq data we identified genetic regulation of hepatic transcription factors, including Nr1h3, contributes to atherogenesis in this cohort. Thus, an integrative approach using DO-F1 mice effectively validates the influence of genetic factors on atherosclerosis in DO mice and suggests an opportunity to discover therapeutics in the setting of hyperlipidemia. Show less
Breast cancer is a common tumor type among women, with a high fatality due to metastasis. Metastasis suppressors encode proteins that inhibit the metastatic cascade independent of the primary tumor gr Show more
Breast cancer is a common tumor type among women, with a high fatality due to metastasis. Metastasis suppressors encode proteins that inhibit the metastatic cascade independent of the primary tumor growth. Raf kinase inhibitory protein (RKIP) is one of the promising metastasis suppressor candidates. RKIP is reduced or lost in aggressive variants of different types of cancer. A few pre-clinical or clinical studies have capitalized on this protein as a possible therapeutic target. In this article, we employed two breast cancer cells to highlight the role of RKIP as an antimetastatic gene. One is the low metastatic MCF-7 with high RKIP expression, and the other is MDA-MB-231 highly metastatic cell with low RKIP expression. We used high-throughput data to explore how RKIP is lost in human tissues and its effect on cell mobility. Based on our previous work recapitulating the links between RKIP and SNAI, we experimentally manipulated RKIP in the cell models through its novel upstream NME1 and investigated the subsequent genotypic and phenotypic changes. We also demonstrated that RKIP explained the uneven migration abilities of the two cell types. Furthermore, we identified the regulatory circuit that might carry the effect of an existing drug, Epirubicin, on activating gene transcription. In conclusion, we propose and test a potential strategy to reverse the metastatic capability of breast cancer cells by chemically manipulating RKIP expression. Show less
Breast cancer is the most common cancer among women and the leading cause of cancer-related deaths worldwide. Despite various therapeutic strategies, its impact on the survival rate and quality of lif Show more
Breast cancer is the most common cancer among women and the leading cause of cancer-related deaths worldwide. Despite various therapeutic strategies, its impact on the survival rate and quality of life of patients remains limited. The Forkhead Box J3 (FOXJ3) transcription factor has been implicated in various cancers, including lung cancer, tongue squamous cell carcinoma, prostate cancer, and colorectal cancer. However, the role of FOXJ3 in breast cancer has not been elucidated. This study aimed to investigate the role of FOXJ3 in breast cancer development, migration, and invasion. FOXJ3 expression was analyzed in patient tissues and breast cancer cell lines. Loss-of-function and gain-of-function studies were performed using MDA-MB-231 and MCF7 cell lines, respectively. Cell proliferation, migration, and invasion assays were conducted, and the effects of FOXJ3 on Snail expression were examined. FOXJ3 is over-expressed in breast cancer tissues compared to normal counterparts and in various breast cancer cell lines. By modulating FOXJ3 expression in breast cancer cell lines, we observed its influence on cell proliferation, migration, and invasion. Microarray analysis and subsequent validation showed that FOXJ3 modulates Snail expression, a well-known transcription factor involved in epithelial-mesenchymal transition. FOXJ3 plays a role in cell proliferation, migration, and the regulation of Snail expression and may be a potential therapeutic target for breast cancer treatment. Show less
Canine lymphoma (CL) is one of the most common malignant tumors in dogs. The cause of CL remains unclear. Genetic mutations that have been suggested as possible causes of CL are not fully understood. Show more
Canine lymphoma (CL) is one of the most common malignant tumors in dogs. The cause of CL remains unclear. Genetic mutations that have been suggested as possible causes of CL are not fully understood. Whole-exome sequencing (WES) is a time- and cost-effective method for detecting genetic variants targeting only the protein-coding regions (exons) that are part of the entire genome region. A total of eight patients with B-cell lymphomas were recruited, and WES analysis was performed on whole blood and lymph node aspirate samples from each patient. A total of 17 somatic variants ( Show less